Trulicity (Dulaglutide) for Children Under 12: Caregiver Administration Guidance

Is Trulicity Approved for Children Under 12?

Trulicity received FDA approval in 2014 for type 2 diabetes in adults, and the agency extended that indication to pediatric patients aged 10 and older in June 2022. Children under age 10 are outside the approved label entirely. The FDA approval announcement confirms this age boundary. No published randomized controlled trial has evaluated safety or efficacy of dulaglutide in children below age 10, so off-label use in that group carries meaningful unknowns.

Why the Age 10 Cutoff Exists

The key pediatric study, AWARD-PEDS, enrolled patients aged 10 to 17 with type 2 diabetes. That trial demonstrated a statistically significant reduction in HbA1c at 26 weeks compared with placebo, providing the regulatory basis for the label extension. Because enrollment stopped at age 10, the FDA had no safety or pharmacokinetic data to support labeling for younger children.

What to Do If Your Child Is Under 10

If a prescriber is considering dulaglutide for a child under 10, ask them to document the clinical rationale and confirm whether an investigational protocol or compassionate-use pathway applies. Standard of care for type 2 diabetes in children under 10 centers on metformin and lifestyle modification per the American Diabetes Association Standards of Care.

Understanding the Dulaglutide Autoinjector Pen

The Trulicity pen is a single-dose, single-use device that contains 0.75 mg or 1.5 mg of dulaglutide in 0.5 mL of solution. A caregiver does not need to draw up a syringe, mix anything, or see a needle. The needle extends automatically when the base cap is removed and the injection button is pressed.

Parts of the Pen

• Base cap (gray): covers the needle; remove only immediately before injection.
• Clear body: lets you inspect the solution, which should appear clear to slightly opalescent. Do not use if the liquid is cloudy, colored, or contains visible particles.
• Green injection button: press and hold until the gray plunger is visible in the window, then hold for 5 additional seconds before removing.
• Needle shroud: automatically retracts after injection to reduce the chance of a needlestick.

Inspecting Before Every Injection

Check the expiration date on the pen label. Confirm the solution color. Look for any cracks in the device body. A pen that was dropped on a hard floor should be discarded, because the internal components may have shifted.

The FDA-approved prescribing information states that Trulicity should be stored refrigerated at 36°F to 46°F and that the pen should be brought to room temperature for 30 minutes before injection to reduce injection-site discomfort.

Step-by-Step Injection Technique for Caregivers

Giving a weekly injection to a child requires a calm environment, consistent technique, and the child's cooperation built over time. The sequence below follows the manufacturer's instructions for use and standard subcutaneous injection principles endorsed by the American Diabetes Association.

Before You Begin

1. Wash both hands with soap and water for at least 20 seconds.
2. Remove the pen from the refrigerator 30 minutes before the planned injection time.
3. Gather supplies: pen, alcohol swab, gauze or cotton ball, sharps container.
4. Choose an injection site and verify it has not been used in the prior two to three weeks.

Preparing the Site

Wipe the skin with an alcohol swab using a circular motion starting at the center. Allow the skin to dry completely, typically 10 to 15 seconds. Do not blow on it or fan it dry. Pinching the skin is not required for most children because the subcutaneous layer is adequate at the recommended sites, but a gentle skin fold may help with very lean children.

Administering the Injection

1. Remove the gray base cap. Do not recap.
2. Place the flat end of the pen firmly against the prepared skin at a 90-degree angle.
3. Press the green button until you hear a click.
4. Continue holding the pen against the skin and count 5 full seconds before lifting.
5. Lift the pen straight up. The needle shroud will lock automatically.
6. If a small amount of blood appears at the site, apply light pressure with gauze. Do not rub.
7. Place the entire used pen directly into the sharps container.

Rotation Schedule

Rotating injection sites is not optional. Repeated injection into the same small area causes lipohypertrophy, a localized thickening of subcutaneous fat that reduces drug absorption and increases glycemic variability. A practical rotation system for weekly dosing: divide the abdomen into a clock face and move one position clockwise each week. The upper thigh and upper arm are alternates when the abdomen is unavailable. Keep a simple injection log with date and site to avoid revisiting a location too soon.

Dosing Schedule and Escalation

Starting Dose

The FDA-approved starting dose for pediatric patients aged 10 and older is 0.75 mg once weekly. This dose may produce meaningful HbA1c reduction on its own. In AWARD-PEDS, dulaglutide 0.75 mg reduced HbA1c by a mean of 0.6 percentage points more than placebo at 26 weeks in a population with baseline HbA1c of approximately 7.9%.

Dose Escalation to 1.5 mg

After at least 4 weeks on 0.75 mg, the prescriber may increase to 1.5 mg once weekly if the child tolerates the starting dose but has not reached the glycemic target. The decision should be made collaboratively with the child's endocrinologist or pediatrician. Do not escalate the dose on your own as a caregiver without a prescriber directive.

Choosing the Weekly Injection Day

Select any day of the week that fits the family's schedule. Consistency matters more than which day is chosen. If the preferred day must change, the new day should be at least 3 days after the most recent injection to maintain an adequate interdose interval. The prescribing label confirms dulaglutide may be given at any time of day, with or without food.

Managing a Missed Dose

Give the missed dose as soon as you remember, provided the next scheduled injection is still at least 3 days away. If fewer than 3 days remain, skip the missed dose entirely and resume the normal weekly schedule. Never give two doses within the same 3-day window.

Common Side Effects and How to Manage Them at Home

GLP-1 receptor agonists act on the gut as well as on pancreatic beta cells, so GI effects are the most frequently reported complaints in pediatric and adult studies alike.

Nausea and Vomiting

Nausea is the most common side effect, reported in approximately 12% to 17% of patients in the adult AWARD program. The AWARD-PEDS trial found similar GI event rates in children. Nausea typically peaks in the first 4 to 8 weeks and diminishes as the body adapts. Practical management strategies include:

• Giving the injection with a small, low-fat meal rather than on a completely empty stomach.
• Avoiding high-fat or high-sugar foods on injection day.
• Offering small, frequent meals and cold or room-temperature foods if nausea is significant.
• Staying well hydrated.

Contact the prescriber if vomiting prevents the child from keeping fluids down for more than 24 hours, or if the child loses more than 5% of body weight in under two weeks.

Diarrhea and Abdominal Discomfort

Diarrhea and loose stools occur in roughly 8% to 14% of patients. These effects are usually mild, self-limiting, and improve within the first month. A temporary reduction in dietary fiber and fatty foods can help. Persistent diarrhea lasting beyond 2 weeks warrants a call to the prescriber to rule out other causes.

Reduced Appetite

Dulaglutide slows gastric emptying and acts on hypothalamic satiety signals. Children on the drug may eat noticeably less. Monitor weight monthly for the first 3 months. Some weight reduction is expected in the context of treating type 2 diabetes; excessive or rapid weight loss in a growing child should be discussed with the care team promptly.

Serious Warnings Caregivers Must Know

Thyroid C-Cell Tumors

Dulaglutide carries a boxed warning for thyroid C-cell tumors based on findings in rodent studies. The human relevance of this signal remains uncertain, but the FDA requires the warning on all GLP-1 receptor agonist labels. The FDA label states: "It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." Children with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) must not receive dulaglutide.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists. Signs in a child include severe, persistent abdominal pain that may radiate to the back, often accompanied by vomiting. If this pattern appears, stop the injection and seek emergency care immediately. Do not wait to see if it resolves on its own.

Hypoglycemia

When used as monotherapy, dulaglutide carries a low intrinsic risk of hypoglycemia because it stimulates insulin secretion in a glucose-dependent manner. The risk increases significantly when dulaglutide is combined with insulin or sulfonylureas. Know the signs of hypoglycemia in children: shakiness, pallor, sweating, confusion, and irritability. Keep fast-acting glucose (glucose tablets or 4 oz of juice) accessible at all times if the child is on combination therapy.

Renal and Hepatic Monitoring

Dehydration from vomiting or diarrhea can impair renal function. If the child has a known kidney condition, notify the prescriber before starting dulaglutide. Report any significant decrease in urine output during an illness to the care team the same day.

Supporting a Child Through Weekly Injections

Weekly injections are stressful for children and caregivers alike. A structured approach reduces anticipatory anxiety and builds cooperation over time.

Building a Routine

Inject on the same day each week at the same time of day. A predictable routine signals to the child that the injection is a normal, manageable event rather than an unpredictable intrusion. Some families link the injection to a recurring family activity, like a weekend breakfast, to create a positive association.

Distraction Techniques

Research supports distraction as an effective non-pharmacologic pain management strategy during pediatric procedural pain. A Cochrane review on non-pharmacological interventions for procedural pain in children found that distraction, including watching videos or blowing bubbles, significantly reduced self-reported pain scores. Offer a choice of distraction activity to give the child a sense of control.

Age-Appropriate Involvement

Children aged 10 and 11 can begin learning the names of the pen parts and the steps of the process. Allowing a child to press the injection button themselves, under direct caregiver supervision, may increase their sense of agency and reduce resistance. Full independence with self-injection is not expected before the mid-teens.

When Resistance Escalates

Persistent, extreme distress around injections in a child with a chronic condition may indicate anxiety that merits referral to a pediatric psychologist. Several children's hospitals have specific programs for needle phobia and diabetes-related distress. Ask the endocrinology team for a referral if weekly injections remain a crisis after the first 4 to 6 weeks.

Storage and Handling in Real-World Family Settings

Refrigerator Rules

Store all unused pens in the original carton in the refrigerator at 36°F to 46°F. Keep pens away from the freezer compartment. Frozen pens must be discarded because ice crystal formation can damage the protein structure of the drug, rendering it less effective or inactive.

Traveling With Dulaglutide

For trips under 14 days, pens can remain at room temperature at or below 77°F (25°C). Use an insulated bag with an ice pack for travel in warm climates, but ensure the pen does not contact the ice directly. At room temperature, the drug degrades faster than in the refrigerator, so use the pen as close to its scheduled dose day as possible during travel.

For travel beyond 14 days, keep pens in a portable medical-grade refrigerator or a hotel mini-fridge. The FDA medication guide is the authoritative reference for storage specifications.

Sharps Disposal

Place used pens in an FDA-cleared sharps disposal container immediately after use. Never place loose pens or needles in household trash. When the container is approximately three-quarters full, follow local regulations for disposal. Many pharmacies offer take-back programs. The FDA sharps disposal guidance provides a state-by-state resource list.

Coordinating With the Pediatric Care Team

Monitoring Schedule

After initiating dulaglutide, the care team will typically schedule a follow-up at 4 weeks to assess tolerability and GI side effects, and again at 12 weeks to review HbA1c response. Standard pediatric diabetes monitoring includes HbA1c every 3 months per the ADA Standards of Care for Children and Adolescents. Blood pressure, weight, and renal function are also tracked at routine visits.

Communicating Side Effects

Keep a brief written log of GI symptoms, appetite changes, and weight for the first 8 weeks. This log gives the prescriber concrete information to decide whether a dose hold, escalation, or alternative agent is appropriate. Specific entries ("child vomited twice on Tuesday, injection was Monday" versus "child felt sick") help the team make faster decisions.

Drug Interactions and Concurrent Medications

Dulaglutide slows gastric emptying, which may reduce the rate of absorption of oral medications taken around injection time. Oral medications with narrow therapeutic windows, such as certain antibiotics or anticonvulsants, may be affected. Inform every prescriber and pharmacist that the child is on a once-weekly GLP-1 receptor agonist so they can adjust timing recommendations for other oral drugs.